Literature DB >> 34208864

The Role of NKT Cells in Glioblastoma.

Emily E S Brettschneider1,2, Masaki Terabe1.   

Abstract

Glioblastoma is an aggressive and deadly cancer, but to date, immunotherapies have failed to make significant strides in improving prognoses for glioblastoma patients. One of the current challenges to developing immunological interventions for glioblastoma is our incomplete understanding of the numerous immunoregulatory mechanisms at play in the glioblastoma tumor microenvironment. We propose that Natural Killer T (NKT) cells, which are unconventional T lymphocytes that recognize lipid antigens presented by CD1d molecules, may play a key immunoregulatory role in glioblastoma. For example, evidence suggests that the activation of type I NKT cells can facilitate anti-glioblastoma immune responses. On the other hand, type II NKT cells are known to play an immunosuppressive role in other cancers, as well as to cross-regulate type I NKT cell activity, although their specific role in glioblastoma remains largely unclear. This review provides a summary of our current understanding of NKT cells in the immunoregulation of glioblastoma as well as highlights the involvement of NKT cells in other cancers and central nervous system diseases.

Entities:  

Keywords:  brain tumor; glioblastoma; glioma; lipid antigen; natural killer T cell (NKT); tumor immunity

Year:  2021        PMID: 34208864     DOI: 10.3390/cells10071641

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  184 in total

Review 1.  Autoimmunity in multiple sclerosis: role of sphingolipids, invariant NKT cells and other immune elements in control of inflammation and neurodegeneration.

Authors:  Maria Podbielska; Joan O'Keeffe; Edward L Hogan
Journal:  J Neurol Sci       Date:  2017-12-22       Impact factor: 3.181

Review 2.  Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis.

Authors:  Elena Bianchini; Sara De Biasi; Anna Maria Simone; Diana Ferraro; Patrizia Sola; Andrea Cossarizza; Marcello Pinti
Journal:  Immunol Lett       Date:  2017-01-21       Impact factor: 3.685

3.  Zika virus-based immunotherapy enhances long-term survival of rodents with brain tumors through upregulation of memory T-cells.

Authors:  Andrew T Crane; Matthew R Chrostek; Venkatramana D Krishna; Maple Shiao; Nikolas G Toman; Clairice M Pearce; Sarah K Tran; Christopher J Sipe; Winston Guo; Joseph P Voth; Shivanshi Vaid; Hui Xie; Wei-Cheng Lu; Will Swanson; Andrew W Grande; Mark R Schleiss; Craig J Bierle; Maxim C-J Cheeran; Walter C Low
Journal:  PLoS One       Date:  2020-10-01       Impact factor: 3.240

4.  Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2.

Authors:  Stefan Fichtner-Feigl; Masaki Terabe; Atsushi Kitani; Cheryl A Young; Ivan Fuss; Edward K Geissler; Hans-Jürgen Schlitt; Jay A Berzofsky; Warren Strober
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

5.  Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission.

Authors:  Manabu Araki; Takayuki Kondo; Jenny E Gumperz; Michael B Brenner; Sachiko Miyake; Takashi Yamamura
Journal:  Int Immunol       Date:  2003-02       Impact factor: 4.823

6.  Tissue-Specific Distribution of iNKT Cells Impacts Their Cytokine Response.

Authors:  You Jeong Lee; Haiguang Wang; Gabriel J Starrett; Vanessa Phuong; Stephen C Jameson; Kristin A Hogquist
Journal:  Immunity       Date:  2015-09-08       Impact factor: 31.745

7.  Cutting edge: V alpha 14-J alpha 281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice.

Authors:  Lennart T Mars; Véronique Laloux; Karine Goude; Sabine Desbois; Abdelhadi Saoudi; Luc Van Kaer; Hans Lassmann; André Herbelin; Agnès Lehuen; Roland S Liblau
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

Review 8.  Bioactive Sphingolipids as Biomarkers Predictive of Disease Severity and Treatment Response in Cancer: Current Status and Translational Challenges.

Authors:  Mirela Sedić; Petra Grbčić; Sandra Kraljević Pavelić
Journal:  Anticancer Res       Date:  2019-01       Impact factor: 2.480

Review 9.  Dendritic cells loaded with tumor derived exosomes for cancer immunotherapy.

Authors:  Hongyu Liu; Ling Chen; Yaojun Peng; Songyan Yu; Jialin Liu; Liangliang Wu; Lijun Zhang; Qiyan Wu; Xin Chang; Xinguang Yu; Tianyi Liu
Journal:  Oncotarget       Date:  2017-09-11

10.  Natural killer T cell activation increases iNOS+CD206- M1 macrophage and controls the growth of solid tumor.

Authors:  Sourav Paul; Sushanta Chhatar; Amrita Mishra; Girdhari Lal
Journal:  J Immunother Cancer       Date:  2019-08-06       Impact factor: 13.751

View more
  1 in total

Review 1.  Advanced Cell Therapies for Glioblastoma.

Authors:  Guangwen Wang; Wenshi Wang
Journal:  Front Immunol       Date:  2022-08-16       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.